MaaT013: Positive Topline Phase 3 results

See more

Enhancing Survival Through Innovative Immune Modulation

We are a clinical-stage microbiome therapeutics company
aiming to improve survival in cancer.

Our strengths

A full ecosystem approach

Oncology focused

AI-Powered Drug Development

cGMP Versatile Manufacturing Capacities

Latest News

January 8, 2025

January 8, 2025: MaaT Pharma Announces Positive Topline Results from the Pivotal Phase 3 ARES Study Evaluating MaaT013 in acute Graft-versus-Host Disease

January 7, 2025

January 7, 2025: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital

December 18, 2024

Replay: KOL insights and MaaT013 Data from ASH 2024 Meeting

Like what you see? See more posts

Our upcoming events

Event
December 3, 2024

35th International Symposium on ALS/MND

• December 6-8, 2024 – International Symposium on ALS/MND
MaaT Pharma
Event
December 3, 2024

ASH Annual Meeting and Exposition

• December 7-10, 2024 – 66th ASH Annual Meeting and Exposition
MaaT Pharma
Event
November 20, 2024

JP Morgan – 2025 Healthcare Conference

• January 13-16, 2025 – JP Morgan, Healthcare Conference
MaaT Pharma

Join the MaaT Pharma adventure!

Bring your talents, your passion and join an inclusive, creative, and multidisciplinary team. We aim to leverage the potential of microbiome to improve the treatment of patients with cancer.

Learn more about our values, our environment and see what we have to offer to you!

Careers